1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2019

Primary Completion Date

February 17, 2027

Study Completion Date

December 31, 2027

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG

galeterone

Therapeutic

DRUG

Gemcitabine

Therapeutic

Trial Locations (1)

University of Maryland Medical Center, Baltimore

All Listed Sponsors

lead

University of Maryland, Baltimore

OTHER